A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Journal of Hematology & Oncology

Runzi Li¹  Jianjun Zou¹  Junye Xiong¹  Hu Zhou²  Yun Zeng³  Xuliang Shen⁴  Ting Niu⁵  Xiaohui Zhang⁶  Ming Hou⁷  Qi Hu⁸  Zhongxing Jiang⁹  Jie Jin^1,10  Li Gao^1,11  Jianmin Luo^1,12  Linhua Yang^1,13  Yi Wang^1,14  Li Liu^1,15  Ying Feng^1,16  Jianda Hu^1,17  Yazhou Yao^1,18  Liansheng Zhang^1,19  Ruixiang Xia^2,20  Peng Cheng^2,21  Ruibin Huang^2,22  Depei Wu^2,23  Changcheng Zheng^2,24  Yan Li^2,25  Xiaobao Xie^2,26  Qingzhi Shi^2,27  Xin Zhou^2,28  Yuansong Bai^2,29  Yu Hu^3,30  Heng Mei^3,30  Guangxun Gao^3,31  Sujun Gao^3,32  Jing Liu^3,33  Xiaofan Liu^3,34  Renchi Yang^3,34 

[1] Clinical Research & Development, Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China;Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China;Department of Hematology, First Affiliated Hospital of Kunming Medical University, KunMing, China;Department of Hematology, Heping Hospital Affiliated To Changzhi Medical College, Changzhi, China;Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, 610041, Chengdu, Sichuan, China;Department of Hematology, Peking University People’s Hospital, Beijing, China;Department of Hematology, Qilu Hospital, Shandong University, Jinan, China;Department of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, China;Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China;Department of Hematology, The Second Affiliated Hospital of Military Medical University PLA, Chongqing, China;Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, China;Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China;Department of Hematopathology, Shaanxi Provincial People’s Hospital, Xi’an, China;Department of Hematopathology, The Second Affiliated Hospital of Air Force Medical University, Xi’an, China;Department of Hematopathology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;Fujian Medical University Union Hospital, Fuzhou, China;Hematology Department, Baoji Central Hospital, Baoji, China;Hematology Department, Lanzhou University Second Hospital, Lanzhou, China;Hematology Department, The First Affiliated Hospital of Anhui Medical University, Hefei, China;Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;Hematology Department, The First Affiliated Hospital of Nanchang University, Nanchang, China;Hematology Department, The First Affiliated Hospital of Soochow University, Suzhou, China;Hematology Department, The First Affiliated Hospital of USTC, Hefei, China;Hematology Department, The First Hospital of China Medical University, Shenyang, China;Hematology Department, The First People’s Hospital of Changzhou, Changzhou, China;Hematology Department, The Second Affiliated Hospital of Nanchang University, Nanchang, China;Hematology Department, Wuxi People’s Hospital, Wuxi, China;Hematology and Oncology, China–Japan Union Hospital of Jilin University, Changchun, China;Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China;The Blood Internal Medicine, The First Affiliated Hospital of Air Force Medical University, Xi’an, China;The First Hospital of Jilin University, Changchun, China;The Third Xiangya Hospital of Central South University, Changsha, China;Thrombosis and Hemostasis Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases, 300020, Tianjin, China;

关键词: Immune thrombocytopenia;    Hetrombopag;    Thrombopoietin receptor agonists;    Platelet response;   

DOI  :  10.1186/s13045-021-01047-9

来源: Springer

【 授权许可】

CC BY